证券代码：301211 证券简称：亨迪药业 公告编号：2023-051 湖北亨迪药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日召开第一届董事会第十七次会议、第一届监事会第十一次会 议，并于 2023 年 5 月 19 日召开了 2022 年年度股东大会，审议通过 了《关于续聘公司 2023 年度审计机构的议案》，续聘大信会计师事 务所（特殊普通合伙）（以下简称"大信会计师事务所"）为公司 2023 年度的审计机构。具体内容详见公司 2023 年 4 月 25 日、2023 年 5 月 19 日披露于巨潮资讯网（http://www.cninfo.com.cn）的相 关公告。 公司于近日收到大信会计师事务所出具的《关于变更 2023 年度 审计签字注册会计师的告知函》，现将具体情况公告如下： 潘杨州先生，拥有注册会计师，具有证券业务服务经验，2014 年取得注册会计师职业资格，从 2012 年至今在大信会计师事务所（特 殊普通合伙）从 ...

湖北亨迪药业股份有限公司 2023 年第三季度报告 | --- | --- | --- | --- | |----------------------------------------------------------------------|-------|------------------|------------------| | 其他综合收益 | | | | | 专项储备 | | 1,709,031.28 | | | 盈余公积 | | 33,549,551.58 | 33,549,551.58 | | 一般风险准备 | | | | | 未分配利润 | | 246,952,612.85 | 198,437,633.83 | | 归属于母公司所有者权益合计 | | 2,326,723,462.93 | 2,276,499,452.63 | | 少数股东权益 | | | | | 所有者权益合计 | | 2,326,723,462.93 | 2,276,499,452.63 | | 负债和所有者权益总计 | | 2,498,883,170.39 | 2,497,721,443.51 | | 法定代表人： ...

| --- | --- | --- | --- | --- | --- | |------------------------------------------|------------------------------------------------------------------------|-----------------------------------|--------------------------|---------------------------------------------------------------------------------|---------------------| | | | | | | | | | | | 照注册号 | | | | 报告期初注册 | 2022 年 02 月 11 日 | 荆门市市场监督 管理局 | 914208006154064 29F | 914208006154064 29F | 914208006154064 29F | | 报告期末注册 | 2023 年 07 月 06 日 | 荆门市市场监督 管理局 | 91 ...

Group 1: Company Overview - As of May 19, 2023, the number of shareholders is 31,819 [2] - The company focuses on the production of ibuprofen and its derivatives, aiming to establish a global production base for antipyretic and analgesic drugs [3] Group 2: Future Projects and Developments - The company plans to advance the construction of projects with an annual capacity of 5,000 tons of ibuprofen and 200 tons of ibuprofen lysinate [3] - It aims to enhance its product system in cardiovascular, anti-tumor, and anticholinergic drugs, with projects like 10 tons/year of abiraterone acetate and 2 tons/year of imatinib mesylate [3] - The company is also working on the development of various formulations, including sustained-release ibuprofen capsules and injection products [3] Group 3: Sales and Marketing Strategy - The sales model for raw materials is primarily direct sales, supplemented by distribution, while formulations are sold domestically through a distribution model [4] - The company emphasizes a customer-centric sales philosophy [4] Group 4: Research and Development Focus - The company prioritizes new drug research, particularly in ibuprofen derivatives and specialty raw materials for cardiovascular and anti-tumor applications [3] - Currently, there are no traditional Chinese medicine products or research initiatives [4] Group 5: Vision and Goals - The company aims to become a significant domestic base for non-steroidal anti-inflammatory raw materials and specialty raw materials, promoting synergistic development between raw materials and formulations [4]

Revenue and Profit Growth - Revenue for the first quarter of 2023 increased by 50.72% to RMB 193,286,953.47 compared to the same period last year[11] - Operating revenue for the first quarter of 2023 was RMB 193,286,953.47, a 50.7% increase compared to RMB 128,246,403.15 in the same period last year[33] - Net profit attributable to shareholders rose by 42.76% to RMB 39,922,932.84 year-over-year[11] - Net profit for the first quarter of 2023 was RMB 39,922,932.84, a 42.7% increase compared to RMB 27,964,503.94 in the same period last year[34] - The company's basic and diluted earnings per share both grew by 41.67% to RMB 0.17[11] - Basic earnings per share for the first quarter of 2023 were RMB 0.17, compared to RMB 0.12 in the same period last year[34] Cash Flow and Financial Position - Operating cash flow turned negative at RMB -15,751,558.42, a decrease of 126.77% from the previous year[11] - Net cash flow from operating activities turned negative at -15,751,558.42, compared to a positive 58,835,705.46 in the previous period[36] - Investment cash flow decreased significantly by 1,845.93% to RMB -15,747,092.81 due to payments for fundraising projects[16] - Net cash flow from investing activities was -15,747,092.81, a significant decrease from -809,231.50 in the previous period[36] - Cash and cash equivalents at the end of the first quarter of 2023 were RMB 1,825,739,376.30, a decrease of RMB 32,349,494.75 compared to the beginning of the period[31] - Monetary funds decreased to 1,825,739,376.30 yuan from 1,858,088,871.05 yuan at the beginning of the year[22] - Total liabilities and owner's equity at the end of the first quarter of 2023 were RMB 2,480,787,021.44, a slight decrease compared to RMB 2,497,721,443.51 at the end of the previous period[33] - Total assets slightly declined by 0.68% to RMB 2,480,787,021.44 compared to the end of the previous year[11] - Total assets decreased to 2,480,787,021.44 yuan from 2,497,721,443.51 yuan at the beginning of the year[22][23] R&D and Strategic Investments - R&D expenses increased by 53.89% to RMB 7,117,899.04 due to the company's "API + Formulation" integration strategy[16] - R&D expenses for the first quarter of 2023 were RMB 7,117,899.04, a 53.9% increase compared to RMB 4,625,339.65 in the same period last year[33] - Cash paid for the purchase of fixed assets, intangible assets, and other long-term assets increased sharply to 15,753,734.40 from 767,134.50[36] Assets and Liabilities - Current assets decreased to 2,198,104,491.56 yuan from 2,226,895,374.35 yuan at the beginning of the year[22] - Non-current assets increased to 282,682,529.88 yuan from 270,826,069.16 yuan at the beginning of the year[22][23] - Current liabilities decreased to 151,736,493.24 yuan from 208,909,427.09 yuan at the beginning of the year[23] - Non-current liabilities remained stable at 12,303,450.57 yuan compared to 12,312,563.79 yuan at the beginning of the year[23] - Shareholders' equity increased by 1.77% to RMB 2,316,747,077.63[11] - Shareholders' equity increased to 2,316,747,077.63 yuan from 2,276,499,452.63 yuan at the beginning of the year[23] - The company's total owner's equity at the end of the first quarter of 2023 was RMB 2,316,747,077.63, an increase of RMB 40,247,625.00 compared to the end of the previous period[33] Operating Activities and Expenses - Prepayments surged by 87.00% to RMB 34,389,436.84, driven by increased advance payments to suppliers[16] - Contract liabilities decreased by 59.88% to RMB 27,969,583.04 due to reduced prepayments from customers[16] - Sales of goods and services received cash of 140,480,784.29, an increase from the previous period's 129,945,261.07[36] - Cash received from other operating activities decreased to 13,439,650.24 from 19,657,544.73 in the previous period[36] - Total cash inflows from operating activities were 153,929,298.28, down from 158,915,828.76 in the previous period[36] - Cash paid for goods and services increased significantly to 100,153,085.60 from 57,535,278.18[36] - Cash paid to employees and for employee benefits rose to 27,871,641.79 from 22,166,248.58[36] - Total cash outflows from operating activities surged to 169,680,856.70 from 100,080,123.30[36] Financial Expenses and Other Items - The company's financial expenses for the first quarter of 2023 were RMB -11,607,887.42, mainly due to interest income of RMB 12,295,014.61[33] - Accounts receivable decreased to 70,891,650.90 yuan from 71,675,405.36 yuan at the beginning of the year[22] - Inventory increased to 122,046,297.99 yuan from 114,701,717.43 yuan at the beginning of the year[22] - Fixed assets decreased to 121,244,762.73 yuan from 126,308,041.13 yuan at the beginning of the year[22] - The company's first-quarter report for 2023 was unaudited[38]

适用 □不适用 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|----------------------------------|-----------------------------|--------------------------|------------------------|---------------------------------|--------------------------------|-----------------------------------|--------------------------|-----------------------------------|------------------------|-----------------------------------| | 承诺投 \n资项目 \n和超募 \n资金投 | 是否已 \n变更项 \n目(含 \n部分变 ...

湖北亨迪药业股份有限公司 2022 年第三季度报告 证券代码:301211 证券简称：亨迪药业 公告编号: 2022-032 湖北亨迪药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1. 董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2. 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明: 保证季度报告中财务信息的真实、准确、 完整。 3. 第三季度报告是否经过审计 □是 ☑否 l 湖北亨迪药业股份有限公司 2022年第三季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |----------------------------------------------------|----------------------|-------------------------|-- ...

湖北亨迪药业股份有限公司 2022 年半年度报告全文 湖北亨迪药业股份有限公司 2022 年半年度报告 2022-028 biocause 2022 年 8 月 l 湖北亨迪药业股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人程志刚、主管会计工作负责人易廷浩及会计机构负责人(会计 主管人员)全纯华声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分,详细描述了公司经营中可能存在的风险及应对措施,敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股,不以公积金转增股本。 2 湖北亭迪药业股份有限公司 2022 年半年度报告全文 目录 | --- | --- | |--------------------------------|-------| | | | | 第一节 重要提示、目录和释义 | ...

湖北亨迪药业股份有限公司 2022 年第一季度报告全文 证券代码：301211 证券简称：亨迪药业 公告编号：2022-019 湖北亨迪药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 ...

湖北亨迪药业股份有限公司 2021 年年度报告全文 湖北亨迪药业股份有限公司 2021 年年度报告 2022-011 2022 年 04 月 1 湖北亨迪药业股份有限公司 2021 年年度报告全文 公积金向全体股东每 10 股转增 0 股。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人程志刚、主管会计工作负责人易廷浩及会计机构负责人(会计主 管人员)全纯华声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 | --- | |-----------------------------------------------------------------------------------------| | | | 公司在本报告"第三节 管理层讨论与分析"中"十一、公司未来发展的展 | | 望"部分，详细描述 ...